Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIMALAYA: Durvalumab and Tremelimumab vs Sorafenib in Advanced Hepatocellular Carcinoma
2024-512212-21-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Nov 2017
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 17
01
Overview
Phase 3, randomised, open-label trial of durvalumab, tiragolumab and sorafenib in hepatocellular carcinoma (HCC) (3 arms), sponsored by AstraZeneca. Primary endpoint: Overall survival. Planned start Nov 2017; status: authorised.
02
Drugs
durvalumabtiragolumabsorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2024-512212-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512212-21-00.